Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 726,067
  • Shares Outstanding, K 47,270
  • Annual Sales, $ 1,540 K
  • Annual Income, $ -135,750 K
  • 36-Month Beta 0.99
  • Price/Sales 465.92
  • Price/Cash Flow 0.00
  • Price/Book 7.14

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.07 +9.17%
on 11/14/17
18.39 -16.48%
on 11/01/17
-2.83 (-15.56%)
since 10/17/17
3-Month
14.07 +9.17%
on 11/14/17
20.25 -24.15%
on 10/02/17
+0.34 (+2.26%)
since 08/17/17
52-Week
7.78 +97.43%
on 12/14/16
20.25 -24.15%
on 10/02/17
+6.38 (+71.05%)
since 11/17/16

Most Recent Stories

More News
Akebia Therapeutics to Participate in Upcoming Investor Conferences

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 15.36 (+1.52%)
Akebia Therapeutics Announces Third Quarter 2017 Financial Results

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 15.36 (+1.52%)
Invirsa Secures Seed Financing to Develop New Approach to Treating Common Infectious Diseases that Affect Millions Annually

Invirsa, an Ohio pharmaceutical company developing a new line of attack against common infectious diseases, has closed $520,000 in seed financing. The founding team is led by experienced...

AKBA : 15.36 (+1.52%)
ARPO : 5.0000 (-9.09%)
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 15.36 (+1.52%)
Biotech Stock Performance Review -- Agenus, Akebia Therapeutics, Acorda Therapeutics, and Advaxis

If you want a Stock Review on AGEN, AKBA, ACOR, or ADXS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Today, DailyStockTracker.com features the Biotech...

ADXS : 3.19 (-1.54%)
AGEN : 3.70 (-0.27%)
AKBA : 15.36 (+1.52%)
ACOR : 17.80 (+3.19%)
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 15.36 (+1.52%)
Akebia Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Non-Dialysis-Dependent Chronic Kidney Disease

--- Phase 3 Study in Japan Expected to Commence by Year-End 2017 -

AKBA : 15.36 (+1.52%)
BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA

The FDA currently shows no intent to hold an AdCom to discuss the BLA for BioMarin's (BMRN) pipeline candidate, pegvaliase.

AKBA : 15.36 (+1.52%)
BMRN : 82.88 (+0.39%)
ACAD : 27.86 (+0.80%)
ADRO : 8.80 (-2.22%)
GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down

GTx (GTXI) posts positive data from a phase II study of enobosarm for treating women with stress urinary incontinence. However, shares dip possibly with the release falling below market estimates.

AKBA : 15.36 (+1.52%)
ACAD : 27.86 (+0.80%)
ADRO : 8.80 (-2.22%)
GTXI : 10.05 (+2.76%)
Ultragenyx's Burosumab Positive in Phase II for XLH and TIO

Ultragenyx's (RARE) burosumab passes the test with positive data from two phase II studies. The candidate gets evaluated for X-linked hypophosphatemia and tumor-induced osteomalacia.

RARE : 48.11 (-0.23%)
AKBA : 15.36 (+1.52%)
ACAD : 27.86 (+0.80%)
ADRO : 8.80 (-2.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 15.79
1st Resistance Point 15.57
Last Price 15.36
1st Support Level 15.00
2nd Support Level 14.65

See More

52-Week High 20.25
Fibonacci 61.8% 15.49
Last Price 15.36
Fibonacci 50% 14.02
Fibonacci 38.2% 12.54
52-Week Low 7.78

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart